Vykat Xr is a drug owned by Soleno Therapeutics Inc. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 12, 2035. Details of Vykat Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7799777 | Salts of potassium ATP channel openers and uses thereof |
Mar, 2029
(3 years from now) | Active |
| US7572789 | Salts of potassium ATP channel openers and uses thereof |
Dec, 2026
(1 year, 5 months from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9757384 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
Nov, 2035
(10 years from now) | Active |
| US12178823 | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
Nov, 2035
(10 years from now) | Active |
FDA has granted several exclusivities to Vykat Xr. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vykat Xr, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vykat Xr.
Exclusivity Information
Vykat Xr holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Vykat Xr's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 26, 2028 |
US patents provide insights into the exclusivity only within the United States, but Vykat Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vykat Xr's family patents as well as insights into ongoing legal events on those patents.
Vykat Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vykat Xr's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 12, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vykat Xr Generics:
There are no approved generic versions for Vykat Xr as of now.
About Vykat Xr
Vykat Xr is a drug owned by Soleno Therapeutics Inc. Vykat Xr uses Diazoxide Choline as an active ingredient. Vykat Xr was launched by Soleno Therap in 2025.
Approval Date:
Vykat Xr was approved by FDA for market use on 26 March, 2025.
Active Ingredient:
Vykat Xr uses Diazoxide Choline as the active ingredient. Check out other Drugs and Companies using Diazoxide Choline ingredient
Dosage:
Vykat Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 25MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 75MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |